Alendronate Use and Risk of Type 2 Diabetes: A Nationwide Danish Nested Case-Control Study
Rikke Viggers1,2, Zheer Al-Mashhadi3,4, Jakob Starup-Linde3,5
1Steno Diabetes Center North Jutland, Department of Endocrinology, Aalborg University Hospital, Aalborg, Denmark.
Frontiers in Endocrinology
|December 6, 2021
Summary
Prior use of alendronate, a bisphosphonate for osteoporosis, was associated with a reduced risk of developing type 2 diabetes. This protective effect appeared to be dose-dependent, suggesting a link between bone metabolism and glucose homeostasis.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Bone Metabolism
Background:
- A potential link exists between glucose homeostasis and bone metabolism.
- Bisphosphonates, such as alendronate, are primary treatments for osteoporosis.
Purpose of the Study:
- To investigate the association between prior alendronate use and the risk of developing type 2 diabetes.
- To explore potential dose-response relationships.
Main Methods:
- Population-based nested case-control study.
- Utilized Danish National Patient Registry and Health Service Prescription Registry data (2008-2018).
- Matched type 2 diabetes cases with controls; analyzed alendronate exposure (ever use, effective use, compliant use) using conditional logistic regression.
Main Results:
- Included 163,588 type 2 diabetes patients and 490,764 controls (mean age 67, 55% male).
- Ever users of alendronate had lower odds of developing type 2 diabetes (aOR 0.64; 95% CI 0.62-0.66).
- A dose-response relationship was observed, with longer effective alendronate use correlating with a lower type 2 diabetes risk.
Conclusions:
- Alendronate may have a protective effect against the development of type 2 diabetes.
- The protective effect appears to be dose-dependent.
- Findings suggest an interplay between bone metabolism regulation and glucose homeostasis.
Related Concept Videos
01:22Diabetes Mellitus: Type 2 and Gestational
3.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.2K
01:19Psychoneuroimmunology: Diabetes and Cancer
81
Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...
81
01:22Diabetes Mellitus: Overview and Type I Subtype
3.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
3.5K
01:23Dipeptidyl Peptidase 4 Inhibitors
287
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
287
01:20Study Designs in Epidemiology
489
Epidemiological study designs are fundamental tools for investigating the distribution, determinants, and control of health conditions in populations. They help researchers understand the relationships between exposures and outcomes, and they broadly fall into two categories: "observational" and "experimental" studies.
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and...
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and...
489
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
338
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
338